Literature DB >> 8162720

Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission.

L P Boulet1, H Turcotte, A Brochu.   

Abstract

This study was designed to determine if there is residual airflow obstruction and/or airway hyperresponsiveness in adults with symptomatic asthma remission, and if age at remission or its duration influence these parameters. We studied 30 subjects, (20 men, 10 women, 28 atopics, aged 18 to 61 years; mean, 32 years) with a history of asthma (mean duration, 2 to 33 years) but who reported no symptoms or medication requirement for > or 2 years. They were individually matched for age, sex, and atopy, to a control group of 30 subjects without history of asthma. Each subject had a respiratory questionnaire and measurements of expiratory flows, lung volumes, and bronchodilator response. Morning/evening peak expiratory flow rates (PEFRs) were recorded for a 2-week period and two methacholine inhalation tests were obtained on separate days. Initial FEV1 and FVC for ex-asthmatics (controls) were, respectively, 91.0 +/- 2.5 percent and 97.8 +/- 2.3 percent (104.1 +/- 1.9 and 104.0 +/- 1.8 percent) of predicted values. Twenty nine ex-asthmatics (15 controls) had occasional respiratory symptoms, not attributed to asthma. Most subjects with asthma remission had evidences of mild airflow obstruction, associated to a methacholine response either increased in 11 (PC20 methacholine, 0.18 to 5.6 mg/ml) or "borderline" in 10 others (PC20 between 8 and 20 mg/ml). Airway responsiveness was normal (PC20 > 20 mg/ml) in 8 ex-asthmatics and in 21 controls (PC20 was under 8 mg/ml and between 10 and 20 mg/ml in, respectively, 5 and 4 controls). Mean reversibility of FEV1 after 200 micrograms of albuterol was 5.7 (range, -1.1 to 14.1 percent) compared with 2.5 (-4.4 to 10.5) in controls. Mean and maximal diurnal variation of PEFR were, respectively, 4.6 +/- 0.4 percent and 12.3 +/- 1.3 percent (controls, 2.9 +/- 0.3 and 7.0 +/- 0.8 percent). There was a significant correlation between PC20 and age at the diagnosis of asthma or at the onset of remission. Airway responsiveness was significantly less when asthma or remission of asthma occurred at a younger age, although there was no difference for baseline FEV1 and no significant correlation between PC20 and duration of asthma or of remission. Perception of bronchoconstriction was similar in both controls and ex-asthmatics. In conclusion, most ex-asthmatics who considered to be in asthma remission showed a persistent increase in airway responsiveness with or without mild airflow obstruction, suggesting that symptom report may be insufficient to determine that asthma is in true remission.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162720     DOI: 10.1378/chest.105.4.1024

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  18 in total

1.  Remission of asthma in the middle aged and elderly: report from the Obstructive Lung Disease in Northern Sweden study.

Authors:  E Rönmark; E Jönsson; B Lundbäck
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

2.  Childhood factors associated with asthma remission after 30 year follow up.

Authors:  J M Vonk; D S Postma; H M Boezen; M H Grol; J P Schouten; G H Koëter; J Gerritsen
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

3.  Inhaled corticosteroids and decline of lung function in community residents with asthma.

Authors:  P Lange; H Scharling; C S Ulrik; J Vestbo
Journal:  Thorax       Date:  2006-02       Impact factor: 9.139

4.  Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids.

Authors:  J K Sont; J Han; J M van Krieken; C E Evertse; R Hooijer; L N Willems; P J Sterk
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

5.  Airway function, inflammation and regulatory T cell function in subjects in asthma remission.

Authors:  Louis-Philippe Boulet; Hélène Turcott; Sophie Plante; Jamila Chakir
Journal:  Can Respir J       Date:  2012 Jan-Feb       Impact factor: 2.409

6.  Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up.

Authors:  J M Vonk; H Jongepier; C I M Panhuysen; J P Schouten; E R Bleecker; D S Postma
Journal:  Thorax       Date:  2003-04       Impact factor: 9.139

7.  Observations on the physiological interactions between obesity and asthma.

Authors:  Katina Nicolacakis; Mary E Skowronski; Albert J Coreno; Erin West; Nizar Z Nader; Robert L Smith; E R McFadden
Journal:  J Appl Physiol (1985)       Date:  2008-09-11

8.  Perception of airflow obstruction and associated breathlessness in normal and asthmatic subjects: correlation with anxiety and bronchodilator needs.

Authors:  L P Boulet; I Cournoyer; F Deschesnes; P Leblanc; A Nouwen
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

Review 9.  The role of lung inflation in airway hyperresponsiveness and in asthma.

Authors:  Nicola Scichilone; Alkis Togias
Journal:  Curr Allergy Asthma Rep       Date:  2004-03       Impact factor: 4.806

10.  Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients.

Authors:  Graeme P Currie; Caroline E Bates; Daniel K C Lee; Catherine M Jackson; Brian J Lipworth
Journal:  Eur J Clin Pharmacol       Date:  2003-03-22       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.